If you have been reading about Immunomodulatory peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C129H215N33O55 | Calculated for the acetylated 28-residue peptide |
| Appearance | White to off-white powder | Lyophilized solid recovered from aqueous buffer |
| Solubility | Freely soluble in water | Typically dissolved in water or buffer before use |
| Typical storage | -20 C or below, desiccated | Protect from light and avoid repeated freeze-thaw cycles |
| Identity testing | Reverse-phase HPLC with mass spectrometry | Retention time and measured mass confirm the sequence |
UTC Climate, Controls & Security was a global provider of building technologies offering fire safety, security, building automation, heating, ventilating, air-conditioning, and refrigeration systems and services. A wholly owned subsidiary of United Technologies Corporation, UTC Climate, Controls & Security was a $16.7 billion company with 55,000 employees serving customers in more than 180 countries. In 2020, United Technologies spun off this subsidiary into the independent Carrier Global Corporation. At the same time United Technologies spun off Otis Worldwide Corporation, and then the remaining United Technologies units (Pratt & Whitney and Collins Aerospace) merged with the Raytheon Company to create Raytheon Technologies.
=== MicroRNA expression === A replication-defective and persistent Sendai virus can be used as a platform for a durable expression of microRNAs, which were able to inhibit expression of targeted genes.
Monocryl is a synthetic, absorbable suture manufactured in Cornelia, Georgia, USA, and trademarked by Ethicon. It is composed of poliglecaprone 25, which is a copolymer of glycolide and ε-caprolactone. It comes both dyed (violet) and undyed (clear) and is an absorbable monofilament suture. It is generally used for soft-tissue approximation and ligation. It is used frequently for subcuticular dermis closures of the face. It has less of a tendency to exit through the skin after it breaks down, in contrast to Vicryl. It is contraindicated for use in cardiovascular and neurologic tissues and for usage in ophthalmic and microsurgery. The use of poliglecaprone suture may be inappropriate in patients who are older, malnourished, or debilitated, as well as in patients with conditions that may delay wound healing. Monocryl has a low tissue reactivity, maintains high tensile strength, and has a half-life of 7 to 14 days. At 1 week, its in vivo tensile strength is at 50–60% undyed (60–70% dyed), 20–30% undyed (30–40% dyed) at two weeks, and essentially completely hydrolyzed by 91–119 days. When removed from the package, it has a high degree of "memory", or coil. It is slippery, making it easier to pass than a braided suture. It has a consistency close to nylon suture material. It is rarely used for percutaneous skin closure and is not used in areas of high tension (e.g., fascia).
Sources: en.wikipedia.org
== In fungi == There are a variety of saprophytic and parasitic organisms that have evolved the habit of growing into their substrates as thin strands for extracellular digestion. This is most typical of the "true" fungi, but it has also evolved in Actinomycetota (Bacteria), oomycetes (which are part of the stramenopile grouping, as are kelp), parasitic plants, and rhizocephalans (parasitic barnacles). Slime molds are traditionally classified as fungi, but molecular-phylogeny work has revealed that most slime molds are not very close to Fungi proper and similar organisms, and that their slime-mold habit has originated several times. Mycetozoa (Amoebozoa), Labyrinthulomycetes (Stramenopiles), Phytomyxea and Guttulinopsis vulgaris (Rhizaria), Acrasidae (Heterolobosea), Fonticula alba (Opisthokonta), and Myxobacteria (Bacteria). Mycetozoa itself contains myxogastrids, dictyostelids, and protostelids, likely with separate origins, with protostelids themselves likely originating several times. Specialized forms of osmotrophy are found in unrelated fungi and animals.
== O == George Andrew Olah (1927–2017), Hungarian and American chemist who worked on the generation and reactivity of carbocations via superacids; 1994 Nobel Prize in Chemistry Marilyn Olmstead (1943–2020), American chemist, expert in small-molecule crystallography Fred Olsen (1891–1986), British-born American chemist, inventor of the ball propellant manufacturing process Lars Onsager (1903–1976), Norwegian and American physical chemist and theoretical physicist who corrected the Debye-Hückel theory of electrolytic solutions, 1968 Nobel Prize in Chemistry Tony Orchard (1941–2005), British inorganic chemist whose research helped to lay the foundations of much modern consumer electronic technology Joan Oró (1923–2004), Spanish (Catalan) biochemist known for studies of the origin of life Hans Christian Ørsted (1777–1851), Danish chemist and physicist who discovered that electric currents create magnetic fields Wilhelm Ostwald (1853–1932), Baltic German physical chemist, 1909 Nobel Prize in Chemistry for contributions to the fields of catalysis, chemical equilibria and reaction velocities Larry E. Overman (born 1943), American organic chemist developing chemical reactions, particularly transition metal catalyzed reactions Geoffrey Ozin (DPhil 1967), British materials chemist known for research on nanomaterials
Two pharmacological agents intended to prevent scarring in mild idiopathic fibrosis are pirfenidone, which reduced reductions in the 1-year rate of decline in FVC and reduced the decline in distances on the 6-minute walk test, but had no effect on respiratory symptoms, and is nintedanib, which acts as an antifibrotic, mediated through the inhibition of a variety of tyrosine kinase receptors (including platelet-derived growth factor, fibroblast growth factor, and vascular endothelial growth factor). A randomized clinical trial showed it reduced lung-function decline and acute exacerbations. Preclinical studies on monoclonal antibodies that target the pulmonary endothelial aggregation receptor 1 (PEAR1) (which plays a crucial role in fibroblast activation and the progression of fibrosis) have shown promising results in slowing disease progression and improving lung function. Anti-inflammatory agents have only limited success in reducing the fibrotic process. Some other types of fibrosis, such as non-specific interstitial pneumonia, may respond to immunosuppressive therapy such as corticosteroids. But only a minority of patients respond to corticosteroids alone, so additional immunosuppressants, such as cyclophosphamide, azathioprine, methotrexate, penicillamine, and cyclosporine may be used. Colchicine has also been used with limited success. Nerandomilast (Jascayd) was approved for medical use in the United States in October 2025.
Voltage-gated ion channels are capable of producing action potentials because they can give rise to positive feedback loops: the membrane potential controls the state of the ion channels, and the state of the ion channels controls the membrane potential. Thus, in some situations, a rise in the membrane potential can cause ion channels to open, thereby causing a further rise in the membrane potential. An action potential occurs when this positive feedback cycle proceeds explosively. The time and amplitude trajectory of the action potential are determined by the biophysical properties of the voltage-gated ion channels that produce it. Several types of channels capable of producing the positive feedback necessary to generate an action potential do exist. Voltage-gated sodium channels are responsible for the fast action potentials involved in nerve conduction. Slower action potentials in muscle cells and some types of neurons are generated by voltage-gated calcium channels. Each of these types comes in multiple variants, with different voltage sensitivity and different temporal dynamics. The most intensively studied type of voltage-dependent ion channels comprises the sodium channels involved in fast nerve conduction. These are sometimes known as Hodgkin-Huxley sodium channels because they were first characterized by Alan Hodgkin and Andrew Huxley in their Nobel Prize-winning studies of the biophysics of the action potential, but can more conveniently be referred to as NaV channels.
Sources: en.wikipedia.org
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.